Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo.
about
Opportunities for the treatment of inflammation in cardiovascular diseaseAlternative splicing and promoter usage generates an intracellular stromelysin 3 isoform directly translated as an active matrix metalloproteinaseTissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosisA microarray study of gene and protein regulation in human and rat brain following middle cerebral artery occlusion.CD40L and Its Receptors in Atherothrombosis-An UpdateTherapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.Functional relationship between matrix metalloproteinase-11 and matrix metalloproteinase-14Overexpression of human matrix metalloproteinase-12 enhances the development of inflammatory arthritis in transgenic rabbitsInhibition of CD40 signaling limits evolution of established atherosclerosis in mice.CD40 ligation induces tissue factor expression in human vascular smooth muscle cells.CD40-TRAF Signaling Upregulates CX3CL1 and TNF-α in Human Aortic Endothelial Cells but Not in Retinal Endothelial Cells.Matrix metalloproteinases and diabetic vascular complications.Tissue-dependent induction of apoptosis by matrix metalloproteinase stromelysin-3 during amphibian metamorphosisAtherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand systemAnti-CD 40 monoclonal antibody.Inflammation in coronary artery disease: potential role for immunomodulatory therapy.Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability.Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis.Regulation of extracellular matrix remodeling and cell fate determination by matrix metalloproteinase stromelysin-3 during thyroid hormone-dependent post-embryonic development.Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.Quantum dot mediated imaging of atherosclerosisMacrophage heterogeneity in atherosclerotic plaques.Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?Tumor necrosis factor superfamily molecules in acute coronary syndromes.Clinical study of the hypothesis of endogenous collateral wind on acute coronary syndrome: a review.Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1.Effect of cyclosporin A intervention on the immunological mechanisms of coronary heart disease and restenosisExpression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis.Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease.Multiple regulatory elements in the murine stromelysin-3 promoter. Evidence for direct control by CCAAT/enhancer-binding protein beta and thyroid and retinoid receptors.Mechanosensitive microRNA-181b Regulates Aortic Valve Endothelial Matrix Degradation by Targeting TIMP3.
P2860
Q28192292-A2DB2AB1-EA34-492B-93E6-223B84AB377AQ28217222-684FBC08-3376-40DB-8527-961C4332E5F3Q28364526-322AB10A-D688-4F88-B63A-B867CAF0FE73Q30838086-46CEEFEE-8478-4198-8253-87DFEE739E1CQ33814059-C6F4679E-4465-446A-819F-634E71407862Q34074837-C637F272-9374-4F3E-9111-AD06FC816D50Q34998476-DB388848-A299-4F4D-B2DF-11C17379FAB1Q35103192-5B3D6628-7928-42A7-8784-DF37C580EE34Q35160907-EE60D144-D524-488A-8889-BB1DFBE15CEAQ35793488-784C3303-8C36-4C6C-8019-9339DC181FE1Q35879683-76D51ED9-CDD2-4592-8819-E80CD0362036Q36081593-CDC278DA-DAFF-4F25-8297-C2C070B665E0Q36141755-EB46CC70-FB76-481E-80B5-AEBEF3187AE0Q36216095-A4F75F07-98FE-41E2-8998-8402C5DD72A9Q36221538-CEDCE920-8C9E-4606-9D32-846B254A2C5AQ36314881-52BAF403-5A1C-4D63-AA61-11B73526CDA9Q36752100-73D0C330-4393-4F3D-A241-6D649C6F189BQ36755904-23A6101B-4B80-4812-9912-01C0790AB2F5Q36962537-38457135-98E1-4E77-AF8B-0DA17DA73DC6Q36991109-957A3385-4809-44D0-8223-828CBDD65DBFQ37283646-69E58841-BA76-4623-B5CE-8655C9A59D86Q37594434-DBBAE60D-3F23-41AA-979A-60ACF3BC923AQ37733224-3E204155-0F64-48BD-BADD-3FDD9A4DA5B8Q37805514-F4614FA6-F395-4334-B2C0-D832D09766CAQ38198008-B2A2BCA3-7F7B-4077-8436-3F80985ADCC6Q38289775-6F6ACE52-6838-4CBB-9DB1-4AD6E84D9BBFQ42370734-F7D462CD-6183-44D1-B83B-17A611B7D119Q42944624-2CAEF287-0AA3-41F0-A77F-7A9675DEE2ADQ46069799-5453467E-77E6-4756-8F8B-F14BEE1FB114Q47828315-907EE956-DF3A-4E61-8FBA-F3F64C057305Q50990562-8460C04B-4455-4356-A0B5-C96922D272E3
P2860
Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Expression of stromelysin-3 in ...... ignaling in vitro and in vivo.
@ast
Expression of stromelysin-3 in ...... ignaling in vitro and in vivo.
@en
type
label
Expression of stromelysin-3 in ...... ignaling in vitro and in vivo.
@ast
Expression of stromelysin-3 in ...... ignaling in vitro and in vivo.
@en
prefLabel
Expression of stromelysin-3 in ...... ignaling in vitro and in vivo.
@ast
Expression of stromelysin-3 in ...... ignaling in vitro and in vivo.
@en
P2093
P2860
P356
P1476
Expression of stromelysin-3 in ...... ignaling in vitro and in vivo.
@en
P2093
E Atkinson
E Levesque
G K Sukhova
U Schönbeck
P2860
P304
P356
10.1084/JEM.189.5.843
P407
P577
1999-03-01T00:00:00Z